WARNING: ASTHMA-RELATED DEATH

Long-acting beta2-adrenergic agonists (LABA), such as vilanterol, one of the active ingredients in BREO, increase the risk of asthma-related death.

...continue reading

Indications

Once-daily BREO 100/25 is for maintenance treatment of airflow obstruction in patients with COPD, and for reducing COPD exacerbations in patients with a history of exacerbations. BREO 100/25 is the only strength indicated for COPD. BREO is NOT indicated for the relief of acute bronchospasm.

References

"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"View all references

823310R0 July 2017